RSV MEDI deltaM2-2

Drug Profile

RSV MEDI deltaM2-2

Alternative Names: M2-2 RSV vaccine - Medimmune; Medi RSV M2-2 vaccine; Medi-RSV-delta-M2-2 vaccine; Respiratory-syncytial virus vaccine M2-2 – Medimmune; RSV MEDI deltaM2-2 vaccine; RSV vaccine intranasal - Medimmune

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Developer MedImmune; National Institute of Allergy and Infectious Diseases
  • Class Attenuated vaccines; DNA vaccines; Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Respiratory syncytial virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In children, In infants, Prevention, In adults) in USA (Intranasal, Drops)
  • 01 Aug 2011 Phase-I clinical trials in Respiratory syncytial virus infections (prevention in infants, children and adults) in USA (Intranasal)
  • 01 Jan 2000 Preclinical trials in Respiratory syncytial virus infections in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top